ReviewCancer discovery2019
Engineering Multidimensional Evolutionary Forces to Combat Cancer.
Review in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- An aging-related gene signature, featuring Cdkn2a, predicts prognosis and immunotherapy response in uterine corpus endometrial carcinoma.Discover oncology · 2026Article
- Peripheral Blood CD8International journal of molecular sciences · 2024Article
- Choline metabolism reprogramming mediates an immunosuppressive microenvironment in non-small cell lung cancer (NSCLC) by promoting tumor-associated macrophage functional polarization and endothelial cell proliferation.Journal of translational medicine · 2024Article
- Strategies and delivery systems for cell-based therapy in autoimmunity.Frontiers in drug delivery · 2024Review
- Pan-cancer analysis and single-cell analysis reveals FAM110B as a potential target for survival and immunotherapy.Frontiers in molecular biosciences · 2024Article
- FAM family gene prediction model reveals heterogeneity, stemness and immune microenvironment of UCEC.Frontiers in molecular biosciences · 2023Article
- Towards precision oncology with patient-derived xenografts.Nature reviews. Clinical oncology · 2022Review
- Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.Science translational medicine · 2022Article
- Experiments from unfinished Registered Reports in the Reproducibility Project: Cancer Biology.eLife · 2021Article
- Massively parallel quantification of phenotypic heterogeneity in single-cell drug responses.Science advances · 2021Article
- A mathematical study on the drug resistant virus emergence with HIV/AIDS treatment cases.Heliyon · 2021Article
- Article
- Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer.Journal of translational medicine · 2020Article
- Treating Cancer as an Invasive Species.Molecular cancer research : MCR · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
With advances in technology and bioinformatics, we are now positioned to view and manage cancer through an evolutionary lens. This perspective is critical as our appreciation for the role of tumor heterogeneity, tumor immune compartment, and tumor microenvironment on cancer pathogenesis and evolution grows. Here, we explore recent knowledge on the evolutionary basis of cancer pathogenesis and progression, viewing tumors as multilineage, multicomponent organisms whose growth is regulated by subcomponent fitness relationships. We propose reconsidering some current tenets of the cancer management paradigm in order to take better advantage of crucial fitness relationships to improve outcomes of patients with cancer. SIGNIFICANCE: Tumor and tumor immune compartment and microenvironment heterogeneity, and their evolution, are critical disease features that affect treatment response. The impact and interplay of these components during treatment are viable targets to improve clinical response. In this article, we consider how tumor cells, the tumor immune compartment and microenvironment, and epigenetic factors interact and also evolve during treatment. We evaluate the convergence of these factors and suggest innovative treatment concepts that leverage evolutionary relationships to limit tumor growth and drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.